Stock Events

Stock Events

Calidi Biotherapeutics 

$1.3850
56
+$0.03+2.59% Friday 19:58
-$0.10-7.58%Friday 23:56After hours

Statistics

Day High
1.385
Day Low
1.385
52W High
27.84
52W Low
1.25
Volume
314
Avg. Volume
-
Mkt Cap
3.58M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17NovExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-6.88
-4.8
-2.73
-0.65
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2021
2022
2023
2024
2025
0Revenue
-25.58MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CLDI. It's not an investment recommendation.
NVIDIA
8
NVDA
Apple
7
AAPL
Rocket Lab
7
RKLB
Tesla
6
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Brainstorm Cell Therapeutics
BCLI
Mkt Cap11.92M
Brainstorm Cell Therapeutics focuses on developing stem cell therapies for neurodegenerative diseases, similar to Calidi's focus on regenerative medicine.
Stem
STEM
Mkt Cap53.62M
Lineage Cell Therapeutics works on cell-based therapies, directly competing in the regenerative medicine space.
Mesoblast
MESO
Mkt Cap2.25B
Mesoblast Limited specializes in regenerative medicine using mesenchymal lineage cells, aligning closely with Calidi's therapeutic approaches.
Fate Therapeutics
FATE
Mkt Cap297.15M
Fate Therapeutics develops programmed cellular immunotherapies, which competes with Calidi's approach in using biotherapeutics for treatment.
CRISPR Therapeutics
CRSP
Mkt Cap5.39B
CRISPR Therapeutics is involved in gene editing, a cutting-edge technology that can be seen as a competitor to traditional stem cell therapies.
Vericel
VCEL
Mkt Cap2.06B
Vericel Corporation produces autologous cell therapies for treatment of severe diseases, directly competing with Calidi's cell therapy approaches.

Holdings

Regions

Sectors

About

Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
Show more...
CEO
Eric E. Poma
Employees
29
Country
United States
ISIN
US3207035078

Listings

BOATS
BOATS
CLDI.BOATS
OTC Link
US
CLDWW
ARCX
US
FLAG
XASE
US
CLDI

0 Comments

Share your thoughts

FAQ

What is Calidi Biotherapeutics stock price today?▼
The current price of CLDI is $1.39 USD — it has increased by +2.59% in the past 24 hours. Watch Calidi Biotherapeutics stock price performance more closely on the chart.
What is Calidi Biotherapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XASE exchange Calidi Biotherapeutics stocks are traded under the ticker CLDI.
Is Calidi Biotherapeutics stock price growing?▼
CLDI stock has risen by +4.14% compared to the previous week, the month change is a -14.51% fall, over the last year Calidi Biotherapeutics has showed a -94.75% decrease.
What is Calidi Biotherapeutics market cap?▼
Today Calidi Biotherapeutics has the market capitalization of 3.58M
When is the next Calidi Biotherapeutics earnings date?▼
Calidi Biotherapeutics is going to release the next earnings report on November 17, 2026.
What were Calidi Biotherapeutics earnings last quarter?▼
CLDI earnings for the last quarter are -2.94 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Calidi Biotherapeutics revenue for the last year?▼
Calidi Biotherapeutics revenue for the last year amounts to 0 USD.
What is Calidi Biotherapeutics net income for the last year?▼
CLDI net income for the last year is -25.58M USD.
How many employees does Calidi Biotherapeutics have?▼
As of September 08, 2026, the company has 29 employees.
In which sector is Calidi Biotherapeutics located?▼
Calidi Biotherapeutics operates in the Health & Wellness sector.
When did Calidi Biotherapeutics complete a stock split?▼
The last stock split for Calidi Biotherapeutics was on July 31, 2026 with a ratio of 1:16.
Where is Calidi Biotherapeutics headquartered?▼
Calidi Biotherapeutics is headquartered in SAN DIEGO, United States.